Diabetes technology has transformed lives, but progress often feels painfully slow. Devices can take years to launch, pump designs stay largely unchanged for more than a decade, and apps update at a pace far behind what we expect from our phones or laptops. It’s not that the ideas aren’t there—it’s the reality of regulations, safety requirements, and the economics of medtech development that slow everything down.

There’s a lot at play here: From the FDA approval process and the rigorous testing required for safety and cybersecurity, to the massive costs of getting devices cleared and reimbursed. These safeguards exist for good reasons, but they also mean even small updates can get bogged down for years. At the same time, innovators are looking for ways to change the system—like universal testing standards and bold efforts such as the T1D Moonshot program, which is exploring how automation could speed innovation without sacrificing safety.

Regulatory expert Dr. Shannon Lantzy who is spearheading the T1D Moonshot joined me to dig into why diabetes tech moves so slowly, the interworking of the FDA and what safeguards are in place, and how projects like hers could reshape the future of med tech. To attend Lantzy’s T1D Moonshot workshop on October 30th, inquire on the Moonshot website. You can listen to the full episode above or watch the video below.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.